Browsing Tag
Immunotherapy
41 posts
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific…
FDA approves Bristol Myers Squibb’s Opdivo for expanded lung cancer treatment, boosting stock and investor sentiment
In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded…
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of…
Agenus announces promising trial results for colon cancer treatment at ESMO Congress
Agenus Inc. (Nasdaq: AGEN), a pioneer in the development of immunological agents for cancer treatment, has recently unveiled…
AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial
In a significant advancement for cancer treatment, AstraZeneca’s Imfinzi (durvalumab) has emerged as the first and only immunotherapy…
Bristol Myers Squibb announces Opdivo FDA approval for urothelial carcinoma
In a significant stride toward enhancing bladder cancer treatment, Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food…
Syncona’s Autolus and BioNTech forge alliance to propel CAR-T therapies
Syncona Ltd, a prominent investor in the life sciences sector, has announced a significant strategic collaboration through its…
Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize…
Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of…
Bristol-Myers Squibb’s Opdivo fails to meet key endpoint in small cell lung cancer trial
Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate…